<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01667315</url>
  </required_header>
  <id_info>
    <org_study_id>Bupivacaine 0,375%</org_study_id>
    <nct_id>NCT01667315</nct_id>
  </id_info>
  <brief_title>Minimum Effective Volume of 0.375% Bupivacaine in Interscalene Brachial Plexus Block</brief_title>
  <official_title>Minimum Effective Volume of 0.375% Bupivacaine in Ultrasound- and Nerve Stimulator-guided Interscalene Brachial Plexus Block for Shoulder Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of ultrasound in regional anesthesia enables reduction in the local anesthetic&#xD;
      volume. The present study aimed to determine the minimum effective volume of 0.375%&#xD;
      bupivacaine with epinephrine for interscalene brachial plexus block for shoulder surgery.&#xD;
      Following approval by the Research Ethics Committee, patients with a physical condition of I&#xD;
      or II according to the American Society of Anesthesiologists, between 21 and 65 years old and&#xD;
      subjected to elective surgery of the shoulder and interscalene brachial plexus block will be&#xD;
      recruited. The volume of the anesthetic will be determined using a step-up/step-down method&#xD;
      and based on the outcome of the preceding block. Positive or negative block results in a 1mL&#xD;
      reduction or increase in volume, respectively. The success of the block is defined as the&#xD;
      presence of motor block in two muscle groups and the absence of thermal and pain sensations&#xD;
      in the necessary dermatomes within 30 minutes of the injection. Diaphragmatic paralysis,&#xD;
      pulmonary function and analgesia will be quantified at 30 minutes, 4 and 6 hours. Data will&#xD;
      undergo statistical analysis in order to determine minimum effective volume of 0.375%&#xD;
      bupivacaine and, secondarily, the maximum volume that maintains the diaphragmatic function,&#xD;
      evaluate diaphragm paralysis and its influence in pulmonary function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimum effective volume of 0,375% bupivacaine</measure>
    <time_frame>30 minutes</time_frame>
    <description>Minimum effective volume of 0,375% bupivacaine with epinephrine in ultrasound-guided interscalene brachial plexus block for shoulder surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum 0,375% bupivacaine volume that maintains the diaphragmatic function</measure>
    <time_frame>Before block, 10, 20 and 30 minutes, 4 and 6 hours after</time_frame>
    <description>Maximum effective volume of 0,375% bupivacaine with epinephrine in ultrasound-guided interscalene brachial plexus block for shoulder surgery without diaphragmatic block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>Before block, 30 minutes, 4 and 6 hours after</time_frame>
    <description>Spirometric evaluation of forced vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diaphragmatic Function</measure>
    <time_frame>Before block, 30 minutes, 4 and 6 hours after</time_frame>
    <description>Diaphragmatic movement on ultrasound</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Shoulder Surgery</condition>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivacaine 0,375%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine 0,375%</intervention_name>
    <description>Positive or negative block results in a 1-mL reduction or increase in volume, respectively.</description>
    <arm_group_label>Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 21 and 65 years&#xD;
&#xD;
          -  Candidates for an elective surgical intervention on the shoulder with indication for&#xD;
             anesthesia via brachial plexus block&#xD;
&#xD;
          -  Physical condition of I or II according to the American Society of Anesthesiologists&#xD;
&#xD;
          -  Body mass index up to 35 kg.m-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Cognitive impairment or active psychiatric condition&#xD;
&#xD;
          -  Infection at the site of the puncture for the block&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Bupivacaine allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Federal University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz Fernando Saldanha de Almeida, MD</last_name>
      <email>luizfsa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcelo Vaz Perez, MD PhD</last_name>
      <email>marcelovazperez@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marcelo V Perez, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>August 13, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2012</study_first_posted>
  <last_update_submitted>August 16, 2012</last_update_submitted>
  <last_update_submitted_qc>August 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Luiz Fernando Saldanha de Almeida</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

